Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay

Hideaki Kato, Kei Miyakawa, Norihisa Ohtake, Hirofumi Go, Yutaro Yamaoka, Satoshi Yajima, Tomoko Shimada, Atsushi Goto, Hideaki Nakajima, Akihide Ryo
doi: https://doi.org/10.1101/2021.09.23.21263927
Hideaki Kato
1Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan
2Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kei Miyakawa
3Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norihisa Ohtake
4Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center, Kanagawa, Japan
5Advanced Medical Research Center, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirofumi Go
6Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yutaro Yamaoka
3Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
7Life Science Laboratory, Technology and Development Division, Kanto Chemical Co, Inc., Isehara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Yajima
8Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoko Shimada
9Nursing Department, Yokohama City University Hospital, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Goto
10Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideaki Nakajima
2Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akihide Ryo
3Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aryo@yokohama-cu.ac.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Levels of 50% neutralizing titer (NT50) reflect a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is expected for determining the level of herd immunity against SARS-CoV-2.

Methods We analyzed samples from 168 Japanese healthcare workers who had completed two doses of the BNT162b2 vaccine. We analyzed immunoglobulin G (IgG) index values against spike protein (SP) using automated chemiluminescent enzyme immunoassay system AIA-CL and analyzed the background factors affecting antibody titer. SP IgG index was compared with 50% neutralization titers.

Results The median SP IgG index values of the subjects (mean age = 43 years; 75% female) were 0.1, 1.35, 60.80, and 97.35 before and at 2, 4, and 6 weeks after the first dose, respectively. At 4 and 6 weeks after the first dose, SP IgG titers were found to have positive correlation with NT50 titer (r=0.7535 in 4 weeks; r=0.4376 in 6 weeks). Proportions of the SP IgG index values against the Alpha, Beta, Gamma, and Delta variants compared with the original strain were 2.029, 0.544, 1.017, and 0.6096 respectively. Older age was associated with lower SP IgG titer index 6 weeks after the first dose.

Conclusions SP IgG index values were raised at 3 weeks after two doses of BNT162b2 vaccination and have positive correlation with NT50. SP IgG index values were lower in the older individuals and against Beta and Delta strain.

Competing Interest Statement

NO is an employee of Tosoh Corporation. YY is an employee of Kanto Chemical Co., Inc. Other authors stated no conflict of interest.

Funding Statement

This work was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number: JP20he0522001.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the institutional review board of Yokohama City University Hospital (Approval number: B210300001).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
Hideaki Kato, Kei Miyakawa, Norihisa Ohtake, Hirofumi Go, Yutaro Yamaoka, Satoshi Yajima, Tomoko Shimada, Atsushi Goto, Hideaki Nakajima, Akihide Ryo
medRxiv 2021.09.23.21263927; doi: https://doi.org/10.1101/2021.09.23.21263927
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
Hideaki Kato, Kei Miyakawa, Norihisa Ohtake, Hirofumi Go, Yutaro Yamaoka, Satoshi Yajima, Tomoko Shimada, Atsushi Goto, Hideaki Nakajima, Akihide Ryo
medRxiv 2021.09.23.21263927; doi: https://doi.org/10.1101/2021.09.23.21263927

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (556)
  • Anesthesia (135)
  • Cardiovascular Medicine (1766)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (313)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (661)
  • Epidemiology (10806)
  • Forensic Medicine (8)
  • Gastroenterology (593)
  • Genetic and Genomic Medicine (2958)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1932)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (632)
  • Infectious Diseases (except HIV/AIDS) (12522)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2803)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1472)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2645)
  • Public and Global Health (5379)
  • Radiology and Imaging (1015)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (126)